Teva Said to Seek Fast EU Approval for Allergan Unit Bid

  • Firms seen offering remedies to EU by Thursday p.m. deadline
  • Deal would create world's largest maker of generic drugs

Teva Pharmaceutical Industries Ltd. will try to win an early European Union approval for its takeover of Allergan Plc’s generics unit by making concessions to regulators this week, according to a person familiar with the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.